Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Videos

The director of the Center for Biologics Evaluation Research at the FDA provided an overview of the Keynote Address he gave at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference. [WATCH TIME: 3 minutes]

Turning Gene Therapy Into Reality: Peter Marks, MD, PhD

Articles

In a phase 3 study, tofersen failed to meet its primary end point of functional change, but did meet its target engagement of SOD1 protein and reductions in neurofilament light.

FDA Potentially Mulling Neurofilament Light as Critical Biomarker in Upcoming AdComm Meeting of Tofersen

More than 90% of patients, ambulatory and non-ambulatory, experienced improvements in Medical Research Council score within 6 months of treatment. 

Supplementing N-163 Beta Glucan Shows Disease-Modifying Effects as Adjuvant in Duchenne Muscular Dystrophy

Differences in baseline characteristics and eligible criteria in presymptomatic infants with spinal muscular atrophy led to differential results on motor and nonmotor clinical outcomes.

Minor Differences in Inclusion Criteria, Baseline Characteristics Impact Motor and Nonmotor Clinical Outcomes in Presymptomatic Spinal Muscular Atrophy 

The neurologist and migraine expert from NYU Langone Health.

The neurologist and migraine expert from NYU Langone Health shared her reactions to the recently approved zavegepant nasal spray (Zavzpret; Pfizer) for the treatment of migraine. [WATCH TIME: 5 minutes]  

Newly Approved Migraine Nasal Spray Offers Alternative Treatment to Injections, Oral Medications: Shae Datta, MD

Slideshows

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

IJMSC Online First: March 2023

Director, Comprehensive Epilepsy Center, NYU Langone Health

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the importance of healthy eating habits and whether all individuals with epilepsy should consider dieting early in their life. [WATCH TIME: 4 minutes]

Importance of Establishing Healthy Eating Habits in Epilepsy: Orrin Devinsky, MD

The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]

Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DO

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

ACTRIMS Forum

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge. 

Rare Diseases

Clinical

5 Qs on Vaccines and Guillain-Barre Syndrome

5 Qs on Vaccines and Guillain-Barre Syndrome

5 Pending FDA Decisions in Neurology to Look for in 2023

Phase 2 Trial for Angelman Syndrome Underway

Out-of-Pocket Costs Steadily Increasing for Neurologic Care

Curious Results in Myasthenia Gravis Study

Initial Results Prove Positive for Low-Dose AXO-AAV-GM1 in GM1 Gangliosidosis

GW Submits sNDA for CBD in Tuberous Sclerosis Complex

5 Pending FDA Decisions in Neurology to Look for in 2023

Phase 2 Trial for Angelman Syndrome Underway

Out-of-Pocket Costs Steadily Increasing for Neurologic Care

Curious Results in Myasthenia Gravis Study

Initial Results Prove Positive for Low-Dose AXO-AAV-GM1 in GM1 Gangliosidosis

GW Submits sNDA for CBD in Tuberous Sclerosis Complex

5 Pending FDA Decisions in Neurology to Look for in 2023

Phase 2 Trial for Angelman Syndrome Underway

Out-of-Pocket Costs Steadily Increasing for Neurologic Care

Curious Results in Myasthenia Gravis Study

Initial Results Prove Positive for Low-Dose AXO-AAV-GM1 in GM1 Gangliosidosis

GW Submits sNDA for CBD in Tuberous Sclerosis Complex